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Background: To quantify the levels of tissue inhibitor of metalloproteinase 4 (TIMP4) and its ratios with free
metalloproteinases (MMP) in the aqueous humor of patients with primary open angle glaucoma (POAG),
pseudoexfoliation syndrome (PXS) and pseudoexfoliative glaucoma (PXG) and to evaluate a possible imbalance
between MMPs and TIMPs in these samples.
Methods: Free MMP2, MMP3, MMP9, TIMP1, TIMP2, TIMP4 concentrations and active levels of MMP2 and MMP3
were determined with immunoassay ELISA and activity assay kits in 168 aqueous samples.
Results: TIMP4 was elevated in glaucoma patients(POAG: 0.95 ± 0.49 PXG: 1.28 ± 1.38 pg/ml. p < 0.001). POAG, PXS
and PXG samples demonstrated higher MMP2, TIMP1 and TIMP2 concentrations (p < 0.001). Samples from the PXS
and PXG groups had a lower total/active MMP2 ratio (p < 0.004 and p < 0.008 respectively). Stoichiometric analysis
showed an overbalance of TIMPsover MMPs in both POAG & PXG groups,especially of TIMP4.
Conclusion: TIMP4 elevation is a novel finding in glaucomatous eyes. A disregulation of extracellular matrix
homeostasis is suggested in POAG, PXS and PXG.
Keywords: Glaucoma, Pseudoexfoliation, Metalloproteinases, TIMP4, TIMP/MMP ratiosBackground
The most important risk factor for the development and
progression of glaucoma is the elevation of the intraocular
pressure (IOP) [1]. IOP regulation is directly associated
with aqueous humor outflow. Although the exact mechan-
ism has not been thoroughly elucidated, studies have shown
that the main resistance to the aqueous humour outflow is
located at the trabecular meshwork (TM), especially the
juxtacanalicular part directly underneath the inner wall of
Schlemm’s canal [2,3]. The special characteristics of the* Correspondence: nfountou@gmail.com
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can potentially determine the outflow facility [4].
In glaucoma, the normal architecture and function of
the juxtacanalicular TM is altered by the pathological ac-
cumulation of connective tissue and the partial loss of
endothelial cells [5,6]. Other local factors such as the ex-
pression of vasoconstrictive molecules and oxidative
stress may also be involved [7,8].
Pseudoexfoliation syndrome (PXS) is an age-related sys-
temic disorder characterized by the abnormal accumulation
of extracellular matrix (ECM) material in extraocular and
ocular tissues. The pseudoexfoliative material might con-
gest the outflow pathways of the TM contributing to the
elevation of the IOP and may be involved in the develop-
ment of pseudoexfoliative glaucoma (PXG) [9,10].entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ous enzymes, known as matrix metalloproteinases
(MMPs). MMPs are a family of endopeptidases that con-
tain an active Zn2+ site which is responsible for their
enzymatic activity [11]. They are synthesized as pro-
enzymes and secreted as inactive molecules which are
activated in vivo by disruption of the cystein-Zn link
[11,12]. The regulation of the proteolytic activity of
MMP is mainly controlled by the presence of tissue in-
hibitors of MMPs (TIMPs) which bind MMPs in a 1:1
stoichiometry [13]. Four TIMPs have been identified in
vertebrates which can inhibit the action of MMPs. All
TIMPs except TIMP3 are in soluble form [13,14]. In bio-
logical fluids, MMPs are found either as free proforms,
activated enzymes or as complexes with TIMPs.
It is well documented that MMPs and TIMPs play an
important role in many ocular pathological processes,
including glaucoma [15]. In vitro and in vivo studies
have shown that MMPs in TM directly control outflow
resistance [16]. Their presence in aqueous humor has
also been established [17,18]. Moreover, the recently
identified TIMP4, which is associated with MMP inhib-
ition along with other biological processes such as apop-
tosis [19], has never been traced or quantified in the
aqueous humor.
Within this context, the objectives of this study were:
a) to trace and estimate the levels of TIMP4 in the aque-
ous humor, b) to investigate the ratios of TIMP4 to
other free MMPs and TIMPs in the aqueous humor, and
c) to investigate the potential imbalance of free forms of
MMPs and TIMPs in eyes with POAG, PXS and PXG.
Methods
Setting
This was a clinic-based, cross-sectional study. The protocol
adhered to the tenets of the Helsinki Declaration and writ-
ten informed consent was given by all participants. The in-
stitutional review board of the Democritus University of
Thrace approved the protocol and the study was conducted
at the Department of Ophthalmology at the University
Hospital of Alexandroupolis, Greece.
Participants
Participants were recruited from the outpatient service
of the Department of Ophthalmology at the University
Hospital of Alexandroupolis, Greece, in a consecutive-if-
eligible basis. All participants were divided into 3 study
groups: POAG, PXS, and PXG. The diagnosis of glau-
coma and pseudoexfoliation syndrome was made by a
glaucoma specialist (GL or VPK) after an evaluation that
included slit-lamp examination with mydriasis, gonio-
scopy, tonometry, central corneal thickness measure-
ment, visual field testing and optic disc assessment with
a 90 diopters non-contact lens. Visual field defects wereassessed with Humphrey perimetry, using the SITA
Standard 30–2 program. The diagnosis of glaucoma and
pseudoexfoliation syndrome were made according to the
European Glaucoma Society guidelines [20].
Exclusion criteria for all participants were: a) history
of optic neuropathy other than glaucoma, b) retinal
pathology, c) corneal opacity, d) penetrating eye surgery
or other ocular operations any time in the past, e) previ-
ous ocular inflammation and f) systemic disorders such
as diabetes mellitus and autoimmune or inflammatory
diseases that could have affected the optic nerve. All
study groups were compared with an age-matched sam-
ple of control participants (CG) recruited from the list
of patients scheduled for routine cataract surgery after
an examination by a glaucoma expert (GL). Controls
had to have no other ocular pathology except age-
related cataract. They were also excluded if they had any
of the systemic disorders listed above. Exclusion criteria
for the PXS group were: IOP > 21 mmHg at any time
point according to the participant’s medical records,
optic disc suspicious for glaucoma, visual field defects
and the use of antiglaucoma medications.
Sample collection
All aqueous humor samples were collected by the same
surgeon (VPK) at the initial steps of scheduled cataract
or combined cataract-trabeculectomy surgery. Preopera-
tive chemoprophylaxis included only topical use of 5%
povidone iodine solution for 30 seconds immediately be-
fore the operation. Anterior chamber paracentesis was
made through clear cornea with a 27G tuberculin syr-
inge avoiding contact with other ocular tissues. The
samples (mean quantity 150 μl) were stored in −73° Cel-
sius. After collecting the aqueous humor sample, the
routine steps of the planned operation were performed.
Quantitative analysis
In order to assess the free total (proform and active) con-
centrations of MMP2, MMP3 and MMP9 in aqueous
humor, 96 well enzyme immunoassay ELISA kits were used
(Quantikine; R&D Systems, Minneapolis, MN). Similar
ELISA kits (Quantikine; R&D Systems, Minneapolis, MN)
were used to determine the concentration of total TIMP1,
TIMP2 and TIMP4. All ELISA measurements included free
forms of molecules. The quantification of active MMP2
and MMP3 was performed with activity assay kits (Biotrak,
Amersham Biosciences, GE Healthcare). The latter quanti-
fied endogenously activated enzyme levels and total levels
(proform and active) without taking into account com-
plexed forms. This strategy may have helped increase the
sensitivity and validity of the study. Sample preparation, di-
lution and enzyme detection were performed according to
the specific assay instructions. More specifically, a 10-fold
dilution was used for MMP2, MMP3, TIMP2 and TIMP4,
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quantification required both 10- and 100-fold dilutions in
order to confirm the results. The aqueous quantity added
to each well was appointed by each ELISA kit (Table 1).
Graphic curves were designed using the Origin 6 soft-
ware (OriginLab Corporation) according to sample op-
tical densities and concentrations. After averaging the
duplicate readings for each standard, control and sam-
ple, the average zero standard optical density was sub-
tracted. By plotting the optical density for the standards
versus the concentration of the standards, the best curve
was drawn. The corresponding concentration for each
enzyme was calculated, after multiplication by the dilu-
tion factor. The detection sensitivity of each kit is pre-
sented in Table 1.
Statistical analysis
The SPSS statistical software (SPSS Inc, Chicago, IL,
v.13) was used for the analysisof results. Sample normal-
ity was assessed with the Kolmogorov Smirnoff test.
Multiple independent samples tests were performed with
the Kruskal-Wallis test and confirmed by two independ-
ent Mann–Whitney rank sum tests. All tests were two-
tailed and statistical significance was considered for p <
0.01 after Bonferroni correction.
Results
One hundred and sixty eight eyes from 168 white partic-
ipants (56% men, mean ± SD age: 75 ± 7.6 years, range:
36 to 88 years) were included. There was no statistical
difference in the mean age of the groups. Demographic
and clinical parameters are shown in Table 2. Quantita-
tive differences in MMPs and TIMPs are presented in
Table 3.
TIMP4 levels
TIMP4 levels were higher in both glaucoma groups (POAG
and PXG) when compared to controls (p = 0.001). In con-
trast, in the PXS group, TIMP4 concentrations presented
no statistical difference from controls (p = 0.936) (Table 3).Table 1 Detection sensitivity for Quantikine ELISA and
Activity Assay Kits (Manufacturer’s data)
MMP2 0.016 – 0.289 ng/mL (mean 0.047 ng/mL)
MMP3 0.002 – 0.045 ng/mL ( mean 0.009 ng/mL)
MMP9 0.156 ng/mL
TIMP1 0.08 ng/mL
TIMP2 0.004 – 0.064 ng/mL (mean 0.011 ng/mL)
TIMP4 2.14 – 10.0 pg/mL (mean 4.91 pg/mL)
Active MMP2 0.19 ng/mL (increased sensitivity protocol)
Active MMP3 0.1 ng/mL (increased sensitivity protocol)
MMP: Matrix metalloproteinase, TIMP: Tissue inhibitor metalloproteinase.Free MMP levels – other TIMP levels
Further analysis was extended to other free MMPs and
TIMPs. In POAG, PXS and PXG samples, the concen-
trations of total free MMP2, TIMP1 and TIMP2were sig-
nificantly higher compared to controls. In PXG eyes,
free MMP3 was also elevated (p < 0.001) compared to
controls (Table 3).
Activity assays
POAG, PXS and PXG patients had higher levels of active
MMP2 (p < 0.001, p = 0.003 and p < 0.001, respectively)
and active MMP3 (p < 0.001) than controls. PXS and
PXG samples though, had lower ratios of active/total
MMP2 (p = 0.004 and p = 0.008) (Table 3).
MMP/TIMP ratios in different study groups
In order to evaluate a possible imbalance in ECM modu-
lation, a thorough evaluation of MMP/TIMP ratios was
performed.
POAG samples showed a decreased ratio of MMP-9/
TIMP-4 compared to controls. In this group, we found
lower ratios of MMP-3 and MMP-9 to the other TIMPs
compared to controls (Table 4).
PXG samples presented similar ratio results as POAG
samples, although the differences in MMP3 to other
TIMPs ratios did not reach statistical significance
(Table 4).
In PXS eyes, an increased ratio of MMP2/TIMP4 was
found. The other MMP/TIMP ratios are showed in
Table 4.
Differences between study groups
Compared to PXS samples, PXG samples demonstrated
higher TIMP4 concentrations (p < 0.001), lower TIMP4
ratios [MMP2/TIMP4 (p < 0.001) and MMP9/TIMP4 (p
< 0.001)] and higher MMP3 levels (p = 0.008). No differ-
ences between POAG and PXG eyes were detected.
Discussion
MMPs play a critical role in TM tissue remodeling. They
do not only function as catalytic proteases, but also as
extracellular processing enzymes that influence cell- to-
cell and cell-to-matrix signaling [21]. Their action is reg-
ulated by gene expression, pericellular accumulation,
biochemical activation and interaction-deactivation with
TIMPs, their endogenous inhibitors. Although the action
of MMPs involves a large variety of connective tissue el-
ements, their secretion depends on the specific substrate
needed to be resolved. Several studies showed that in a
given environment, the concentration of active enzyme
may be directed by the concentration of a preferred
ECM element, since specific MMPs degrade some sub-
strates more efficiently than others [22-24]. The cells
keep a high reserve of surface-anchored MMPs which
Table 2 Clinical parameters for the study groups
Control POAG PXS PXG
(n = 44) (n = 36) (n = 44) (n = 44)
AGE(years) 75.27 ± 5.66 (63–86) 75.74 ± 7.4 (59–86) (p = 0.96) 75.76 ±5.15 (61–84) (p = 0.96) 75.96 ± 6.37 (64–88) (p = 0.96)
IOP (mm Hg) 14 ± 2.35 (9–17) 19 ±6.6 (10–40) 14.7 ± 3 (9–20) 21.1 ±9,3 (8–38)
Optic nerve c/d ratio 0.25 ± 0.053 (0.1–0.4) 0.62 ± 0.17 (0.4-0.9) 0.28 ±0.071 (0.2–0.4) 0.68 ± 0.16 (0.4–0.9)
Number of topical medications nil 1 (49%) nil 1 (9%)
2 (23%) 2 (13%)
3 (11%) 3 (47%)
4 (6%) 4 (22%)
POAG: Primary open angle glaucoma, PXS: Pseudoexfoliation, PXG: Pseudoexfoliation glaucoma, c/d: cup-to-disc ratio. Results are presented as mean ± SD (range).
p values refer to the comparison between each study group versus controls with the Kolmogorov-Smirnoff test.
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vironment biochemically permits allosteric or other
types of activation [21]. Thus, free MMPs in a cellular
environment reflect ready-for-action molecules.
Glaucoma and MMP regulation have been highly associ-
ated since most of the proposed pathogenic mechanisms
suggest enzyme dysfunction [15,25]. The presence of
MMPs and TIMPs has been established both in the TM
and aqueous humor in normal and pathologic conditions.
In the aqueous humor, the amount of proteolytic activity
and inhibition may reflect the ECM state of remodeling
from surrounding anterior segment tissues. MMPs and
TIMPs could originate from anterior chamber structures
such as the TM and corneal endothelial cells, or from a
blood-aqueous barrier breakdown [17]. Although the exact
origin is not known, it has been suggested that in glaucoma,
the main reason for increased enzymatic levels is local tis-
sue up-regulation [17].
ECM disorders within the TM and surrounding tissues
concur in POAG, PXS and PXG [17,18]. In PXG, there is a
relationship between PEX material accumulation andTable 3 Levels of total free (proform/active), active matrix me
in aqueous humor
Control POAG
MMP2 7.13 ± 1.5 (5.3-10.2) 23.7 ±10.5 (7.16-44) (p < 0.001)*
MMP3 3.11 ±0.8 (1.6-4.5) 7.5 ±15.8 (1.3-61) (p = 0.07)
MMP9 0.45 ± 0.25 (0.2-0.97) 0.7 ± 0.6 (0.2-2.1) (p = 0.08)
TIMP1 16.3 ± 6.1 (9.3-33.5) 33.6 ± 19.3 (11–75) (p < 0.001)*
TIMP2 3.7 ± 1.1 (2–5.7) 6.5 ± 3.1 ( 2.1-13.2) (p < 0.001)*
TIMP4 0.48 ± 0.25 (0.22-0.98) 0.95 ± 0.49 (0.24-1.76) (p < 0.001)
Active MMP2 0.21 ± 0.01 (0.2-0.24) 0.27 ± 0.06 (0.2-0.42) (p < 0.001)*
Active MMP3 0.29 ± 0.01 (0.26-0.3) 0.32 ± 0.02 (0.28-0.37) (p < 0.001)
Act/tot. MMP2 0.008 ± 0,00086 0.006 ±0,00279 (p = 0.03)
Act/tot. MMP3 0.008 ± 0,00183 0.008 ± 0,00061 (p = 0.93)
MMP: Matrix metalloproteinase, TIMP: Tissue inhibitor metalloproteinase, POAG: Prim
glaucoma. Concentrations (ng/mL) are presented as mean ± SD(range).
p values refer to the Kruskal-Wallis multiple sample test for each study group versu
*: statistically significant.glaucoma development and progression [9]. However, there
are eyes with excessive accumulation of exfoliation material
that do not develop glaucoma; therefore other predisposing
factors leading to glaucoma conversion seem to exist [26].
Recent evidence suggests that trabecular cellular func-
tion is compromised especially at the juxtacanalicular
and Schlemm’s canal region [27]. In trabecular mesh-
work specimens, besides endothelial dysfunction, there
is significant cell apoptosis [8,28]. Furthermore, both
PXS and PXG are characterized by impairment of ocular
hemodynamics, suggesting ischemic stress at the anter-
ior ocular segment [10,19,29]. Similar pathological phe-
nomena can occur in other systemic diseases, like
cardiovascular disorders, where the recently discovered
TIMP4 seems to play a significant role. TIMP4 overex-
pression is highly associated with the regulation of
apoptosis, inflammation-induced cell death and inhib-
ition of endothelial cell migration [19,30,31]. Further-
more, its capacity to block the conversion of pro-MMPs
to their active forms supports its role in ECM matrix
modulation [32].talloproteinases and tissue inhibitor metalloproteinases
PXS PXG
15.8 ± 9.8 (6.1-29.3) (p < 0.001)* 23.4 ±17.3 (7.1-56.7) (p < 0.001)*
6.8 ± 11.7 (1.3-44.,2) (p = 0.11) 9.8 ± 16.8 (1.5-72) (p < 0.001)*
0.6 ± 0.33 (0.2-1.3) (p = 0.2) 0.6 ± 0.35 (0.17-1.5) (p = 0.2)
31.2 ± 14.5 (12–58.5) (p < 0.001)* 37 ± 15 (15–60.3) (p < 0.001)*
5.3 ± 2.1 (2.4-8.9) (p < 0.001)* 6.3 ± 3.1 (2.3-12.2) (p < 0.001)*
* 0.48 ± 0.2 (0.13-0.76) (p = 0.93) 1.28 ± 1.38 (0.4-5.9) (p < 0.001)*
0.24 ± 0.03 (0.19-0.3) (p < 0.003)* 0.25 ± 0.04 (0.19-0.33) (p < 0.001)*
* 0.32 ± 0.01 (0.3-0.35) (p < 0.001)* 0.32 ± 0.2 (0.29-0.35) (p < 0.001)*
0.005 ±0,00234 (p = 0.004)* 0.005 ± 0,00299 (p = 0.008)*
0.007 ± 0,0023 (p = 0.1) 0.008 ± 0,00072 (p = 0.93)
ary open angle glaucoma, PXS: Pseudoexfoliation, PXG: Pseudoexfoliation
s controls. Statistical significance: p < 0.01 after Bonferroni correction.
Table 4 MMP/TIMP ratios for the study and control groups
CONTROL POAG PXS PXG
MMP2/TIMP1 0,464 ± 0,1 0,805 ± 0,31 (p > 0.1) 0,73 ± 0,753 (p > 0.1) 0,618 ± 0,360 (p > 0.1)
MMP2/TIMP2 2,07 ± 0,65 4,04 ± 2(p = 0.069) 2,8 ± 1,09 (p = 0.06) 4,34 ± 3,59 (p = 0.06)
MMP2/TIMP4 18,42 ±8,4 33,54 ± 25,61 (p = 0.031) 34,47 ± 19,07 (p < 0.001)* 28,36 ± 26,88 (p = 0.73)
MMP3/TIMP1 0.21 ± 0,085 0.17 ± 0.2 (p = 0.001)* 0.226 ± 0.4 (p < 0.001)* 0.26 ± 1.15 (p = 0.02)
MMP3/TIMP2 0.95 ± 0.48 0.88 ± 1.16 (p = 0.007)* 1.68 ± 3.17 (p = 0.01)* 2.07 ± 3.9 (p = 0.39)
MMP3/TIMP4 8,47 ± 4,86 11,93 ± 24,07 (p > 0.1) 14,16 ± 31,4 (p > 0.1) 16,85 ± 40,98 (p > 0.1)
MMP9/TIMP1 0.028 ± 0.014 0.023 ± 0.017 (p < 0.001)* 0.02 ± 0.019 (p < 0.001)* 0.02 ± 0.018 (p < 0.001)*
MMP9/TIMP2 0.13 ± 0.07 0.104 ± 0.059 (p < 0.001)* 0.12 ± 0.06 (p < 0.001)* 0.104 ± 0.063 (p < 0.001)*
MMP9/TIMP4 1.18 ± 0.99 1,12 ± 1.08 (p = 0.01)* 1.42 ± 0.7 (p = 0.4) 0.8 ± 0.59 (p < 0.001)*
MMP: Matrix metalloproteinase, TIMP: Tissue inhibitor metalloproteinase, POAG: Primary open angle glaucoma, PXS: Pseudoexfoliation, PXG:
Pseudoexfoliation glaucoma.
Values are presented as mean ± SD.
p values refer to the Mann Whitney test for each study group versus controls. Statistical significance: p < 0.01 after Bonferroni correction.
*: statistically significant.
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nostaining kit, we were able, for the first time, to quan-
tify TIMP4 in aqueous humor samples. We found that
TIMP4 was only elevated in glaucoma patients. In PXS
patients, TIMP4 levels were statistically similar to con-
trols. Furthermore, both POAG and PXG patients
showed a decreased ratio of MMP9/TIMP4, a result not
seen in PXS samples. Instead, in PXS patients the
MMP2/TIMP4 ratio is increased. POAG and PXG pa-
tients had similar MMP2/TIMP4 and MMP3/TIMP4 ra-
tios with controls even though there was an increase in
the concentration of MMP2 in the POAG group and
MMP3 in the PXG group. The increase in TIMP4 levels
seems to compensate (or even over-compensate)for the
respective increase in MMP concentrations in eyes with
POAG and PXG [32]. Thus, besides all other possible
TIMP4 properties, the increased levels of this inhibitor
may contribute to the altered balance of TIMPs and
MMPs in the aqueous humor of glaucoma patients. Our
results may suggest an important link between glaucoma
and TIMP4 action.
In POAG, several studies have shown that the levels of
total MMP2 and MMP3 and the levels of TIMP1 and
TIMP2 are generally up-regulated. Furthermore, in PXS
and PXG, total MMP-2, total MMP-3, TIMP-1 and TIMP2
levels in aqueous humor were also significantly elevated
compared to samples from conntrols [17,18]. Our study in-
vestigated the concentrations of free MMP and TIMP in all
study groups. In POAG patients it is found that TIMP1,
TIMP2 and MMP2 were statistically elevated compared to
controls. Furthermore, activity assays showed that the ratio
of active/total free MMP2 and MMP3 were not signifi-
cantly altered in POAG. PXG patients presented higher free
MMP3 levels. PXS and PXG patients also had significantly
higher concentrations of free MMP2, TIMP1, TIMP2 and
active MMP2 and MMP3but a lower ratio of active/total
MMP2. This conclusion agrees with previous reports[17,18] and suggests that even though there is a higher pro-
duction of ECM catabolic enzymes in POAG, their proteo-
lytic action is insufficient for adequate matrix turnover.
The importance of stoichiometric balance between
MMP2/TIMP2 was shown by a number of reports [11,17].
In our investigation, the MMP2/TIMP2 ratio in POAG pa-
tients was not increased. Therefore, it can be assumed that
the elevation of TIMP2 levels is in essence a compensatory
reaction to the elevation of MMP2 levels. The comparison
of the MMP/TIMP ratios was extended to all studied mole-
cules, because to a certain extent, all TIMP members can
inhibit different MMPs. The analysis showed that despite
MMP elevation there were no higher levels of MMP/TIMP
ratios; instead decreased ratios of MMP3 and MMP9 over-
TIMP1 and TIMP2 could suggest a major regulatory role
of enzyme inhibitors.
Among the objectives of our study was to reveal po-
tential differences within study groups. A recent study
with POAG and PXG patients indicated that MMPs/
TIMPs ratios from TMs pecimens are decreased in
PXG, while in samples of POAG eyes, the MMP-1/
TIMP-1 ratio and the total MMP1 + 2 + 3 + 9/total
TIMP1 + 2 + 3ratio were increased when compared to
PXG eyes [33]. Moreover, MMP immunostaining ana-
lysis of aqueous humor samples of the same patients
presented no differences between the two glaucoma
groups [33]. Our results also showed similar MMP/
TIMP aqueous profile between the two groups.
Regarding the comparison between the PXG and PXS
groups, the most important differences were found in the
TIMP4 concentrations and ratios. No differences were dis-
covered in active MMPs concentrations, or in MMP9/
TIMP1-2 ratios. Another notable difference was that
MMP3 levels were significantly elevated in PXG, but not in
PXS samples. These results suggest that TIMP4 and
MMP3 may have a different regulatory role in pseudoexfo-
liative eyes with and without glaucoma.
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wide range of MMP levels within the study groups. This
wide variation may reflect differences in phenotypes, dis-
ease stage or disease duration. Secondly, the majority of
patients were under treatment with topical medication
(i.e. prostaglandin analogues, b-blockers etc.) that could
potentially affect aqueous composition and MMP con-
centration [34].Conclusions
Our study suggests that there is an imbalance between
MMP-related proteolytic activity and its regulation by
members of the TIMP family of enzymes in eyes with
POAG and PXG. Our novel finding is the elevation of
TIMP4 in the aqueous samples of glaucomatous eyes.
TIMP4, as a potential inhibitor of MMP activity, could
be implicated in ECM homeostasis disorders in glau-
coma. Its further role in glaucoma pathology merits fur-
ther investigation.
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